9:51 PM
 | 
Jan 11, 2019
 |  BC Extra  |  Financial News

Kaleido, Cirius seeking NASDAQ listings

Kaleido Biosciences Inc. (Lexington, Mass.) and Cirius Therapeutics Inc (San Diego, Calif.) each proposed NASDAQ IPOs on Friday.

Kaleido, which is designing therapies to modulate the metabolic output and profile of the microbiome, is seeking up to $100 million in its offering. The company's most advanced compounds, KB195 and KB174 for hyperammonemia-related disorders, are derived from a class generally regarded as...

Read the full 282 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >